Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III ...
Motorists struggling with one of 188 medical conditions must inform the DVLA or risk facing fines of up to £1,000. Those ...
Clinicians in Europe may soon gain access to a first-in-class neonatal Fc receptor (FcRn) inhibitor for generalized myasthenia gravis (gMG). Imaavy (nipocalimab; Janssen-Cilag International) received ...
World Myasthenia Gravis Day is celebrated every June 15 th. Myasthenia gravis (MG) is an autoimmune illness that affects approximately 1.5 to 2 million people globally. The disorder is characterized ...
Treatment with cemdisiran was associated with a statistically significant improvement in MG-ADL total score compared with placebo. Topline results were announced from a phase 3 trial evaluating ...
Regeneron Pharmaceuticals said a late-stage study of the investigational cemdisiran monotherapy for generalized myasthenia gravis hit its key goals. Regeneron on Tuesday said the Phase 3 study in ...
Regeneron has reported a phase 3 win in generalized myasthenia gravis (gMG), positioning the pharma to file for FDA approval of its siRNA candidate in the increasingly competitive neuromuscular ...
Amid the increasingly competitive myasthenia gravis drug development space, siRNA candidate cemdisiran met phase III endpoints, with the monotherapy showing numerically higher results than a ...
Seeking to build out its pipeline-in-a-product Vyvgart, Argenx is returning to its roots with plans to pursue an expanded approval in the drug’s initial myasthenia gravis indication. On Monday, Argenx ...
Treatment with efgartigimod IV was associated with a statistically significant and clinically meaningful improvement in MG-ADL total score compared with placebo. Topline results were announced from a ...
Monica Seles first noticed the symptoms of myasthenia gravis — a neuromuscular autoimmune disease she discussed during a recent interview with The Associated Press — while she was swinging a racket ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results